About YUANPIN
Yuanpin Cell Biotechnology Group Co., Ltd. (Yuanpin Biotech) is a high-tech enterprise specializing in the storage of human biological resources including stem cells and immune cells, manufacture and preparation of cell formulations and derived products, clinical cell technology research, cell therapies and their clinical translation, and management of bio-health big data. As an industry pioneer, Yuanpin Biotech has established China's first stem cell industrial park — Zhongnan Yuanpin Stem Cell Science and Technology Park, constructed in compliance with international architectural standards for stem cell industrialization platforms, and operates government-certified facilities including the "Hunan Provincial Cell and Tissue Bank", "Hunan Provincial Cell Preparation Center", and "Hunan Provincial Engineering Research Center for Stem Cells and Regenerative Medicine".
Learn more
CORE MODULE
Leadership
Milestones
January 2025
On January 27, Yuanpin Biotech's independently developed Class 1 biological new drug, "Human Amniotic Mesenchymal Stem Cell Injection", had its IND application for an additional indication officially accepted by the Center for Drug Evaluation (CDE), proposing its use for the treatment of chronic obstructive pulmonary disease (COPD).
December 2024
On December 19, Yuanpin Biotech's independently developed "Human Amniotic Mesenchymal Stem Cell Injection" became the world's first to obtain an IND approval, filling the gap of Class 1 stem cell new drugs in clinical trials in Hunan Province.
December 2024
On December 18, Vice Governor Jiang Difei of Hunan Provincial People's Government and his delegation visited the Zhongnan Yuanpin Stem Cell Science and Technology Park to survey the development of the biopharmaceutical industry chain.
December 2024
On December 11, Yuanpin Biotech was successfully selected as one of the "Gazelle" enterprises in Changsha City for the year 2024.
December 2024
On December 10, Yuanpin Biotech's first overseas service center (Malaysia) was established!
September 2024
The Safety Management Regulation for the Isolation, Preparation, and Storage of Immune Cells (group standard) drafted with the participation of the Changsha Institute of Industrial Technology for Stem Cell and Regenerative Medicine was released!
September 2024
Yuanpin Biotech's independently developed Class 1 biological product, "Human Amniotic Mesenchymal Stem Cell Injection", had its IND application officially accepted by the CDE of the National Medical Products Administration (acceptance No.: CXSL2400674).
August 2024
The Induction, Activation, and Cultivation Methods and Release Criteria of Autologous NK Cells (group standard) drafted and formulated with the participation of the Changsha Institute of Industrial Technology for Stem Cell and Regenerative Medicine was officially released!
June 2024
Yuanpin Biotech's project "Study on Critical Equipment and Process for Intelligent and Large-Scale Preparation of Cell Products" was successfully selected into the 2024 Hunan Provincial Key Research and Development Program.
May 2024
Yuanpin Biotech reached a strategic cooperation agreement with the Hunan Academy of Chinese Medicine!
April 2024
Yuanpin Biotech was recognized as a "Specialized-Refined-Unique-Innovative" SME (2024) in Hunan Province.
January 2024
The Life Science and Technology Ethics Committee of Yuanpin Biotech, one of the first batch of technology ethics review institutions (2023) in Hunan Province, held its first review meeting.
November 2023
The company's registered name was changed to Yuanpin Cell Biotechnology Group Co., Ltd. on November 6, 2023 to align with its corporate strategy and business development objectives, and to support nationwide business operations.
September 2023
Yuanpin Biotech and Yuantai Biotech formed a strategic partnership to collaborate in the field of immune cell therapies, establishing an end-to-end industry chain encompassing cell storage, drug R&D, and clinical translation.
May 2023
Yuanpin Biotech was recognized as a Hunan Provincial Enterprise Technology Center for 2023, demonstrating its technological innovation capabilities.
June 2023
The 7th Biosafety Forum was hosted by Yuanpin Biotech, contributing to the creation of a new biosafety landscape.
March 2023
The Technical Specifications of Cleanroom Design for Cell Culture (national standard) drafted with the participation of Yuanpin Biotech was officially released!
February 2023
Yuanpin Biotech was honored as a "Demonstration Enterprise for Trade Secret Protection in Hunan Province".
January 2023
Hunan Provincial Party Committee Deputy Secretary and Governor Mao Weiming visited the Zhongnan Yuanpin Stem Cell Science and Technology Park to survey the development of the biopharmaceutical industry.
October 2022
Yuanpin Biotech has been granted approval by China's Ministry of Science and Technology to establish and operate a cell bank (under the Human Genetic Resources Preservation program), becoming the first enterprise in Hunan Province to obtain this qualification.


















